Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Albert C M Ong"'
Autor:
Thomas Bais, Esther Meijer, Bart J. Kramers, Priya Vart, Marc Vervloet, Mahdi Salih, Bert Bammens, Nathalie Demoulin, Polina Todorova, Roman-Ulrich Müller, Jan Halbritter, Alexander Paliege, Emilie Cornec-Le Gall, Bertrand Knebelmann, Roser Torra, Albert C. M. Ong, Fiona E. Karet Frankl, Ron T. Gansevoort
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-12 (2024)
Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) leads to progressive renal cyst formation and loss of kidney function in most patients. Vasopressin 2 receptor antagonists (V2RA) like tolvaptan are currently the only available
Externí odkaz:
https://doaj.org/article/8b677e8c18f64fe082d69bef19eb97bf
Autor:
Yang Liu, Andres Käch, Urs Ziegler, Albert C M Ong, Darren P Wallace, Alexandre Arcaro, Andreas L Serra
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e73173 (2013)
The mammalian target of rapamycin (mTOR) signaling pathway is aberrantly activated in polycystic kidney disease (PKD). Emerging evidence suggests that phospholipase D (PLD) and its product phosphatidic acid (PA) regulate mTOR activity. In this study,
Externí odkaz:
https://doaj.org/article/a546f237ed6a4c50ac5fabc86144f933
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-14 (2023)
Abstract Background Rare diseases present a challenge to guideline implementation due to a low prevalence in the general population and the unfamiliarity of healthcare professionals. Existing literature in more common diseases references barriers and
Externí odkaz:
https://doaj.org/article/bd2a9281942a4d2780ac456c290d7c22
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
In Drosophila blood, plasmatocytes of the haemocyte lineage represent the functional equivalent of vertebrate macrophages and have become an established in vivo model with which to study macrophage function and behaviour. However, the use of plasmato
Externí odkaz:
https://doaj.org/article/ebc28af2a39645d3be88630f07fa3d29
Publikováno v:
PLoS ONE, Vol 19, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/41026a72da604134b6d516106ef436b2
Autor:
Qianying Wang, Baojuan Zou, Xiaoya Wei, Hongrong Lin, Changmiao Pang, Lei Wang, Jinglin Zhong, Huamu Chen, Xuefei Gao, Min Li, Albert C. M. Ong, Zhihui Yue, Liangzhong Sun
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 11 (2023)
Background: Nephronophthisis (NPH) is the most common genetic cause of end-stage renal disease (ESRD) in childhood, and NPHP1 is the major pathogenic gene. Cyst formation at the corticomedullary junction is a pathological feature of NPH, but the mech
Externí odkaz:
https://doaj.org/article/49e016d498484747a7c8bbfe8c06eed1
Publikováno v:
Clinical Kidney Journal. 16:901-904
ADPKD is the most common hereditary kidney disease and a major cause of kidney failure world-wide. Significant kidney enlargement occurs decades preceding loss of kidney function. However, the earliest clinical manifestations of disease have been les
Autor:
Manoj K Valluru, Noelle KX Chung, Mark Gilchrist, Laura Butland, Jackie Cook, Anna Takou, Abhijit Dixit, Michael N Weedon, Albert C M Ong
Publikováno v:
Journal of Medical Genetics. 60:397-405
BackgroundMonogenic disorders are estimated to account for 10%–12% of patients with kidney failure. We report the unexpected finding of an unusual uromodulin(UMOD)variant in multiple pedigrees within the British population and demonstrate a shared
Publikováno v:
Clinical Kidney Journal. 16:61-68
Background Tolvaptan, a vasopressin V2 receptor antagonist, was approved in 2015 by the UK National Institute for Health and Care Excellence for use in patients with autosomal dominant polycystic kidney disease (ADPKD) and rapid disease progression.
Publikováno v:
Clinical Kidney Journal. 15:1160-1168
Background Everolimus is a potential alternative to embolization and nephrectomy for managing tuberous sclerosis complex (TSC)-associated renal angiomyolipoma (AML). In 2016, National Health Service England approved its use through regional centres f